Stay updated with breaking news from Scottd Eads. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Federal Circuit issued numerous precedential opinions last week, two of which answered long simmering questions about inter partes reviews (IPRs). Below we discuss a case...
Amgen Inc. v. Sanofi , Appeal No. 2020-1074 (Fed. Cir. Feb. 11, 2021) In this week’s Case of the Week, the Federal Circuit affirmed a district court’s JMOL ruling that asserted claims of two related pharmaceutical patents were invalid because their shared specification did not enable the full scope of the claims. The patents were directed to synthetic antibodies used in high cholesterol treatments that operate by binding to specified amino acids (or “residues”) of enzyme PCSK9, thereby blocking PCSK9 from binding to LDL cholesterol receptors (“LDLR”) and permitting those receptors...